BHVN

Biohaven Pharmaceutical Holding Company Ltd

Healthcare


Presented:08/13/2020
Price:$62.16
Cap:$3.64B
Current Price:$50.71
Cap:$4.79B

Presented

Date08/13/2020
Price$62.16
Market Cap$3.64B
Ent Value$4.36B
P/E RatioN/A
Book ValueN/A
Div Yield0%
Shares O/S58.53M
Ave Daily Vol754,822
Short Int21.33%

Current

Price$50.71
Market Cap$4.79B
Biohaven Pharmaceutical Holding Co. Ltd. is a clinical-stage biopharmaceutical company, which engages in the research and development of late-stage product candidates targeting neurological diseases, including rare disorders. It focuses on a pipeline of product candidates that represent mechanistic platforms, calcitonin gene-related peptide receptor antagonists, and glutamate modulators. The company was founded in September 2013 and is headquartered in New Haven, CT.

Publicly traded companies mentioned herein: AbbVie Inc (ABBV), Amgen Inc (AMGN), Biohaven Pharmaceuticals Holding Co Ltd (BHVN), Biogen Inc (BIIB), Johnson and Johnson (JNJ), Eli Lilly and Company (LLY), Royalty Pharma plc (RPRX), Sanofi S.A. (SAN FP)

Highlights

The presenter is long shares of BioHaven (BHVN) following the approval and successful launch of its acute migraine drug - NURTEC ODT (rimegepant). He views NURTEC ODT as a “best in class oral drug” for migraines which is poised to gain significant market share given a superior treatment profile compared to AbbVie’s/Allergan’s Ubrelvy. High prescription uptake since launch, formulary coverage expansion backed by a strong marketing campaign, and IP protection until 2033 all support his bullish revenue growth outlook. Given these factors, he models at least 50% upside from its current share price in the low $60s based on a DCF basis (to >$100).

Nurtec was approved in February 2020 and has been taking market share from Ubrelvy every single week, as well as injectable CGRPs like Amgen’s Aimovig.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

  • Signing up and creating account with us unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Request access to DeMatteo Research for full access

Request Access

Already have an account?

Idea Discussion

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Commentor 1 - 2 weeks ago

Signing up and creating account with us, unlocks this content for you. Contact us today for full access to DeMatteo Research and more.

Idea Discussions display submitted commentary from our investor community.

To read and participate in the discussion with the presenter and investor base, request access to DeMatteo

Request Access

Already have an account?

An error occurred loading this content. Try again later or contact us.